ArticleFrontiers in oncology2026

Beyond a negative trial: timing, molecular residual disease, and antibody biology in adjuvant immunotherapy for resected NSCLC.

Satı Coşkun Yazgan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.